Is sjögren's disease the overlooked CTD associated with an hypersensitivity pneumonitis pattern?

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Leflunomide-hydroxychloroquine: a replicable hope in Sjögren's disease?

The SjD Map: an interactive pathway tour into Sjögren's disease signalling mechanisms

A genetic variant of BAFF is associated with the risk of lymphoma in Sjögren disease

Distinct molecular pathways supporting Sjögren's Disease clusters and disease progression

Update on the Aetiopathogenesis of Sjögren Disease: From Interferon Signaling to Epithelial Dysfunction

Salivary gland organoids and the future of modeling autoimmune epithelitis in Sjögren's disease

The immune cell landscape analysed by imaging mass cytometry in the muscle of patients with inclusion body myositis associated or not with Sjögren's disease

["MALT lymphoma in Sjögren disease: To treat or not to treat?": The pros]

Machine learning to classify the focus score and Sjögren's disease using digitalised salivary gland biopsies: a retrospective cohort study

Association between anti-SSA/SSB antibody profiles and patient-reported outcomes in primary Sjögren's disease

Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)

Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data

Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis

Impact of Sjögren's disease on quality of sexual life using the Qualisex score

Characterisation of airway disease associated with Sjögren disease

Obinutuzumab in patients with Sjogren's disease immunised against rituximab

Development of a web-based ecological momentary assessment tool to measure day-to-day variability of the symptoms in patients with Sjögren's disease

Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study

m(6)A RNA methylation controls salivary gland epithelial cell function and has a protective role in Sjögren's disease

Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren's disease

Immune Checkpoint Inhibitor-induced Sicca Syndrome

Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

Association Between Bruton's Tyrosine Kinase Gene Overexpression and Risk of Lymphoma in Primary Sjögren's Syndrome

Impact of patient ancestry on heterogeneity of Sjögren's disease

Expert Perspective: Challenges in Sjögren's Disease

Comparison between primary Sjögren's disease patients with high or low level of dryness

Efficacy of daratumumab in refractory primary Sjögren disease

French national diagnostic and care protocol for Sjögren's disease

Hyperosmolar environment and salivary gland epithelial cells increase extra-cellular matrix remodeling and lymphocytic infiltration in Sjögren's syndrome

Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study

Baseline characteristics of the TRANSLATE2 cohort: A prospective study on rheumatoid arthritis-associated interstitial lung disease

Lessons from organoid engineering for rheumatic disease

Macrophage Cell Culture and Characterization by Serum Human AB in Health and Disease

CAR T-cell therapy in autoimmune diseases: where are we and where are we going?

Sicca induced by immune checkpoint inhibitors

Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies

Isolated anti-SS-B (La) antibodies: rare occurrence and lack of diagnostic value

Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokines

Transient migratory osteoporosis of epiphyseal lower limbs during FLOT chemotherapy for gastric cancer

French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

PET/CT in Inflammatory and Auto-immune Disorders: Focus on Several Key Molecular Concepts, FDG, and Radiolabeled Probe Perspectives

Liposomal AntagomiR-155-5p Restores Anti-Inflammatory Macrophages and Improves Arthritis in Preclinical Models of Rheumatoid Arthritis

[(18)F]FDG-PET/CT in Polymyalgia Rheumatica: An Update and Future Aspects

[Inflammatory diseases of the salivary]

Mutations in the B30.2 and the central helical scaffold domains of pyrin differentially affect inflammasome activation

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Obinutuzumab in patients with Sjogren's disease immunised against rituximab

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Leflunomide-hydroxychloroquine: a replicable hope in Sjögren's disease?

JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events

JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Cascade: A Potential Mechanism for Major Adverse Cardiac Events

PD1(+) TIGIT(+) CD4(+) T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis

Machine learning to classify the focus score and Sjögren's disease using digitalised salivary gland biopsies: a retrospective cohort study